Advances in Enhancing Hemocompatibility of Hemodialysis Hollow-Fiber Membranes

Hemodialysis, the most common modality of renal replacement therapy, is critically required to remove uremic toxins from the blood of patients with end-stage kidney disease. However, the chronic inflammation, oxidative stress as well as thrombosis induced by the long-term contact of hemoincompatible...

Full description

Saved in:
Bibliographic Details
Published in:Advanced fiber materials (Online) 2023-08, Vol.5 (4), p.1198-1240
Main Authors: Ji, Haifeng, Li, Yupei, Su, Baihai, Zhao, Weifeng, Kizhakkedathu, Jayachandran N., Zhao, Changsheng
Format: Article
Language:English
Subjects:
Adsorption
Anticoagulants
Blood
Cellulose
Chemistry and Materials Science
Coagulation
Contact stresses
Dialysate
Dialyzers
Hemodialysis
Hollow fiber membranes
Kidney diseases
Market entry
Materials Engineering
Materials Science
Membranes
Mortality
Nanoscale Science and Technology
Oxidative stress
Peritoneal dialysis
Permeability
Polymer Sciences
Protein adsorption
Proteins
Quality of life
Renewable and Green Energy
Review
Textile Engineering
Thrombosis
Vitamin E
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hemodialysis, the most common modality of renal replacement therapy, is critically required to remove uremic toxins from the blood of patients with end-stage kidney disease. However, the chronic inflammation, oxidative stress as well as thrombosis induced by the long-term contact of hemoincompatible hollow-fiber membranes (HFMs) contribute to the increase in cardiovascular diseases and mortality in this patient population. This review first retrospectively analyzes the current clinical and laboratory research progress in improving the hemocompatibility of HFMs. Details on different HFMs currently in clinical use and their design are described. Subsequently, we elaborate on the adverse interactions between blood and HFMs, involving protein adsorption, platelet adhesion and activation, and the activation of immune and coagulation systems, and the focus is on how to improve the hemocompatibility of HFMs in these aspects. Finally, challenges and future perspectives for improving the hemocompatibility of HFMs are also discussed to promote the development and clinical application of new hemocompatible HFMs. Graphical Abstract
ISSN:2524-7921
2524-793X
2524-793X
DOI:10.1007/s42765-023-00277-5